Participate in polls relating to real-time continuous glucose monitoring and see how your answers relate to your colleagues.

According to the webcast

with Richard Bergenstal, MD; Steven Edelman, MD and Boris Kovatchev, PhD:
A therapeutic Continuous Glucose Monitor (CGM) may be covered by Medicare when which of the following criteria is/are met:
The beneficiary has diabetes mellitus
The beneficiary has been using a home blood glucose monitor (BGM) and performing frequent (four or more times a day) BGM testing
The beneficiary is insulin-treated with multiple daily injections of insulin or a continuous subcutaneous insulin infusion pump
The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of therapeutic CGM testing results
All of the above

Submit is supported by independent educational grants from Ascensia Diabetes Care, Insulet Corporation, Madrigal Pharmaceuticals and Stanford University.
©2023 CogniMed Inc. All rights reserved.